Professional Documents
Culture Documents
Lupin Limited is a transnational pharmaceutical company based in Mumbai. It is the 2nd largest Indian pharma company by market capitalization, the 14th largest generic pharmaceutical company globally and; the 5th largest generic pharmaceutical company in the US by prescription-led market share. It has the distinction of being the fastest growing generic pharmaceutical player in the two largest pharmaceutical markets of the world the US and Japan; and is the 5th largest and the fastest growing generic pharmaceutical player in South Africa.
Headquartered at the state-of-the-art Lupin Research Park in Pune, India, the Company's research program is home to over 1,400 scientists. The Company's global research operations are spread over multiple research facilities in India and Japan. During FY 2013, the Company invested 7.5% of its net sales in Research & Development and related spends, amounting to 7,098 million. FY 2013 was a record year in terms of progress made all around, be it our pace of filing DMFs (Drug Master Files) and ANDAs (Abbreviated New Drug Applications), progress in our drug discovery and development program, milestones in our drug delivery program and approvals in our biotechnology program.
Generics Research Process Research Pharmaceutical Research Advanced Drug Delivery Systems (ADDS) Research Intellectual Property Management Novel Drug Discovery and Development (NDDD) Biotechnology Research
Process Research
API Process research capabilities are a vital component of the business strategy that provides a sustainable, long-term competitive advantage. The program supports the company's generic research program by developing non-infringing and cost competitive APIs. Highlights, FY 2013 In FY 2013, the Company filed 15 US DMFs taking the cumulative total to 138 DMF filings. The Company also filed 5 EDMFs, 3 COSs, 2 Australia DMFs and 1 Japan DMF during the year Development of specialised and complex APIs like Prostaglandins and a new class of Anti-Retro Virals meant for the US, EU, Japan and other advanced markets
Spending Pattern Differentiation is the heart of our research efforts at Lupin. We have created a truly unique world-class research program, designed to ensure a sustainable pipeline of high-value opportunities to maximise growth. 27,775million cumulative R&D spend in the last 6 years. 7.5% R&D expenditure as a percentage of Net Sales ie Development and related spends, amounting to Rs 7,098 million 29 first-to-file products 1,181 cumulative patents filed as on March 31, 2013 10 pipeline of NDDD / NCE programs in various phases of drug discovery & development.
Pharmaceutical Research
FY 2013 was a landmark year for the Pharmaceutical Research Group as it continued in its single-minded focus to create a meaningful pipeline of differentiated products for both advanced and emerging markets. The group focuses on working on difficult to develop products, first to file products and differentiated therapy areas. In the past five years, the group has added therapy areas like Oral Contraceptives, Ophthalmics, Inhalation (MDIs, DPIs and Nasal Sprays) and Dermatology. The Group ensures that its filings are in line with all global regulatory requirements and one of the key initiatives in FY 2013 was adopting processes and procedures in line with the US FDA's Quality By Design (QBD) requirements.
Highlights, FY 2013
Filed 21 ANDAs with the US FDA and 10 European Union applications The cumulative number of ANDA filings with the US FDA now stands at 176, with 78 approvals received to date. This is in spite of the fact that the Company withdrew 16 ANDA's during the year after re-evaluating their business potential Cumulative first-to-files opportunities now stand at 29 Total cumulative filings within the European Union stands at 53, with 38 approvals received so far Ramped up filings for key markets like Japan, Australia, India, South Africa and other emerging markets
Businesses
Lupins businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug deliverysystems to biotechnology. The companys drugs reach 70 countries with a footprint that covers Advanced Markets such as USA, Europe, Japan, Australia as well as Emerging Markets including India, the Philippines and South Africa to name a few.
Europe
Lupins focus in the European Union encompasses Anti-Infectives, Cardiovascular, and CNS therapy areas, along with niche opportunities in segments like Oral Contraceptives, Dermatology and Ophthalmics. The companys presence in France is by way of a trade partnership; in Germany, it operates through its acquired entity Hormosan Pharma GmbH (Hormosan); while the UK business is a direct-to-market initiative.
Japan
Lupin is the fastest-growing Top 10 generic pharmaceuticals player in Japan (IMS). Lupin operates in Japan through its subsidiary, Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), a company Lupin acquired in 2007, and Irom, Pharmaceutical Co. Ltd (IP), acquired in 2011. Kyowa has an active presence in Neurology, Cardiovascular, Gastroenterology and the Respiratory therapy segments. I'rom is a niche injectables company with significant presence in the DPC hospital segment.
SouthAfrica
Lupin's South African subsidiary, Pharma Dynamics (PD) is the fastest growing and the 5th largest generic company in the South African market (IMS). The company is a market leader in the Cardiovascular segment and has a growing presence in Neurology, Gastroenterology and the Over the Counter (OTC) segments.
Australia
Lupin entered the Australian market through its subsidiary, Generic Health Pte. Ltd. (GH). It subsequently acquired the worldwide marketing rights to the over 100 year old Australian brand Goanna, used for pain management.
Philippines
Lupin's Philippines subsidiary Multicare Pharmaceuticals (Multicare), is a branded generic company focused on Women's Health, Pediatrics, GastroIntestinal and Diabetes care. FY 2012 also marked its foray into the Neurology segment when it entered into a strategic marketing partnership with Sanofi.
Key highlights Highlights, FY 2013 Filed 15 DMFs and 21 ANDAs in the US; received approvals for 16 ANDAs including 2 NDAs (New Drug Applications) during FY 2013. The Company also filed 10 MAAs (Marketing Authorisation Applications) with European Authorities, including nine DCPs (Decentralised Procedure Applications) Filed two exclusive first-to-files for the generic version of Apriso and Viread 150mg, 200mg & 250mg strengths Received initial project milestones payments aggregating over USD 6.5 million for two drug delivery products Completed Phase-I studies in Europe for a program in the CNS area, which is being advanced to Phase II clinical trial now Lupin's biotechnology group received its first marketing authorisation for an oncology product following the successful completion of a Phase III clinical trial in India.